Get the Daily Brief
Latest Biotech News
Atlas Venture Closes $400 Million Opportunity Fund to Support Biotech Portfolio
Atlas Venture announced the close of a $400 million Opportunity Fund III to support follow-on investments in its existing portfolio of biotech startups. The fund aims to provide additional capital...
FDA Unveils New Review Pathway for Ultra-Rare Disease Therapies
The Food and Drug Administration introduced the Rare Disease Evidence Principles (RDEP) program to offer a more flexible and coordinated review process for drugs targeting ultra-rare genetic...
Treeline Biosciences Reveals Clinical Candidates, Raises $200 Million Extension
After years of secrecy, Treeline Biosciences disclosed its first three clinical-stage oncology drug candidates, including a protein degrader targeting BCL6 in lymphoma, a KRAS inhibitor with broad...
AI-Powered High-Throughput Platform Accelerates Antibody Discovery
Researchers at the University of Illinois Urbana-Champaign developed oPool+ display, a high-throughput antibody synthesis and specificity characterization platform that can generate and screen...
Wave Life Sciences Updates RNA Editing Therapy Data for Alpha-1 Antitrypsin Deficiency
Wave Life Sciences reported data from ongoing phase Ib/IIa trials of its RNA editing oligonucleotide, WVE-006, for alpha-1 antitrypsin deficiency (AATD). The therapy demonstrated durable increases...
FDA Commissioner Moves to Publish Drug Rejection Letters to Enhance Transparency
Amid ongoing efforts to increase regulatory transparency, FDA Commissioner Marty Makary announced plans to publicly release complete response letters (CRLs) for drug applications at the time they...
Novartis and Arrowhead Sign $200 Million Deal to Develop RNAi Therapy for Parkinson’s Disease
Novartis entered a global collaboration with Arrowhead Pharmaceuticals, investing $200 million upfront to develop ARO-SNCA, an siRNA-based therapy targeting alpha-synuclein for synucleinopathies...
FDA Introduces Single-Arm Trial Acceptability for Ultra-Rare Disease Drug Approvals
Building on previous rare disease guidance, the FDA unveiled the Rare Disease Evidence Principles (RDEP), facilitating streamlined approval for therapies treating ultra-rare conditions affecting...
Targeting Diseased Cells with Engineered Protein Crunch: A New Therapeutic Pathway
Kyoto University researchers have engineered a synthetic protein, named Crunch, that reprograms innate immune phagocytic cells to selectively engulf and remove diseased living cells. This...
Sucralose Consumption Linked to Blunted Cancer Immunotherapy Response
New research from the University of Pittsburgh reveals that sucralose, a common artificial sweetener, disrupts the efficacy of cancer immunotherapies by altering the gut microbiome. The team...
FDA Initiates Public Disclosure of Drug Rejection Letters for Increased Transparency
The U.S. Food and Drug Administration (FDA) has commenced publishing complete response letters—which detail reasons for rejecting drug applications—in real time alongside companies' receipt of...
Atlas Venture Raises $400 Million Opportunity Fund to Strengthen Portfolio Biotechs
Atlas Venture, a prominent biotechnology venture capital firm, has closed a $400 million Opportunity Fund to provide financial support for existing portfolio companies. This fund is specifically...
Treeline Biosciences Raises $200 Million, Unveils Clinical Candidates in Oncology
Stepping out of stealth mode, Treeline Biosciences, a Massachusetts-based oncology biotech, announced a $200 million Series A extension, bringing total funding to $1.1 billion. The company...
Novartis and Arrowhead Collaborate on RNAi Therapeutics for Neurodegenerative Diseases
Novartis has entered a global licensing and collaboration agreement with Arrowhead Pharmaceuticals to develop RNA interference therapies utilizing Arrowhead's Targeted RNAi Molecule (TRiM)...
Mapping Brain-Wide Neural Activity During Decision-Making in Mice
An international consortium, the International Brain Laboratory, has produced the first comprehensive brain-wide map of single-neuron activity during complex decision-making in mice. Utilizing...
Kyoto University Discovers Synthetic Protein Tool to Harness Phagocytosis for Targeted Cell Removal
Scientists at Kyoto University unveiled a novel protein-based therapeutic, Crunch, engineered to redirect phagocytes to selectively engulf living, disease-causing cells. By replacing the natural...
FDA Proposes New Rare Disease Drug Review Pathway Accepting Single-Arm Trials
The FDA announced the Rare Disease Evidence Principles (RDEP) program, a new collaborative review process between drug and biologics centers for ultra-rare diseases affecting fewer than 1,000 U.S....
Atlas Venture Raises $400 Million to Support Biotech Portfolio Amid Market Challenges
Atlas Venture, a prominent biotech investment firm based in Cambridge, Massachusetts, announced the closure of a $400 million Opportunity Fund dedicated to backing its existing portfolio...
Treeline Biosciences Unveils Clinical Candidates, Secures $200 Million Extension Raising Total to $1.1 Billion
Treeline Biosciences, a Massachusetts-based oncology company, revealed details about its first clinical candidates after operating in relative secrecy. The company announced a $200 million Series...
FDA Advances Transparency with Public Release of Drug Rejection Letters
The Food and Drug Administration (FDA) announced a significant policy change to publish complete response letters (CRLs) for ongoing drug applications publicly and in real time. This initiative...